Abiopharma

🔍 RAIGUEL DARREN S (Executive)

Company: EPLUS INC (PLUS)

Report Date: 2026-05-08

Detailed Transactions and Holdings:

• Sold 71 shares of Common Stock at $88.5031 per share (Direct)
  Date: 2026-05-08 | Code: S | equity_swap_involved: false | shares_owned_after: 56,961.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 157 shares of Common Stock at $89.3728 per share (Direct)
  Date: 2026-05-08 | Code: S | equity_swap_involved: false | shares_owned_after: 56,804.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Sold 56 shares of Common Stock at $90.1963 per share (Direct)
  Date: 2026-05-08 | Code: S | equity_swap_involved: false | shares_owned_after: 56,748.00 | transaction_form_type: 4 | Footnotes: F1, F5, F3
• Sold 374 shares of Common Stock at $88.8536 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: false | shares_owned_after: 56,374.00 | transaction_form_type: 4 | Footnotes: F1, F6, F3
• Sold 450 shares of Common Stock at $90.1427 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: false | shares_owned_after: 55,924.00 | transaction_form_type: 4 | Footnotes: F1, F7, F3
• Sold 176 shares of Common Stock at $91.775 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: false | shares_owned_after: 55,748.00 | transaction_form_type: 4 | Footnotes: F1, F8, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-08 | Code: H | shares_owned_after: 39,531.00

Footnotes:

• F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
• F2: The transaction was executed in multiple trades at prices ranging from $88.02 to $89.01 per share, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased and prices at which the transaction was effected.
• F3: The shares are held in a revocable trust, of which the reporting person and his spouse are the sole trustees and beneficiaries.
• F4: The transaction was executed in multiple trades at prices ranging from $89.02 to $89.99 per share, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased and prices at which the transaction was effected.
• F5: The transaction was executed in multiple trades at prices ranging from $90.02 to $90.34 per share, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased and prices at which the transaction was effected.
• F6: The transaction was executed in multiple trades at prices ranging from $88.41 to $89.16 per share, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased and prices at which the transaction was effected.
• F7: The transaction was executed in multiple trades at prices ranging from $89.75 to $90.50 per share, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased and prices at which the transaction was effected.
• F8: The transaction was executed in multiple trades at prices ranging from $91.77 to $91.78 per share, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased and prices at which the transaction was effected.